

Eline van Overbeeke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7216322/publications.pdf>

Version: 2024-02-01

22
papers

607
citations

687220

13
h-index

677027

22
g-index

23
all docs

23
docs citations

23
times ranked

636
citing authors

#	ARTICLE	IF	CITATIONS
1	Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. <i>Drug Discovery Today</i> , 2019, 24, 1324-1331.	3.2	90
2	Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review. <i>Drug Discovery Today</i> , 2019, 24, 57-68.	3.2	69
3	Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists. <i>BioDrugs</i> , 2017, 31, 447-459.	2.2	65
4	Information needs of physicians regarding the diagnosis of rare diseases: a questionnaire-based study in Belgium. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 99.	1.2	65
5	Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study. <i>Frontiers in Pharmacology</i> , 2019, 10, 1395.	1.6	48
6	Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review. <i>BMC Medical Informatics and Decision Making</i> , 2019, 19, 189.	1.5	36
7	An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process?. <i>Health Policy</i> , 2020, 124, 1325-1332.	1.4	28
8	Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study. <i>Haemophilia</i> , 2021, 27, 129-136.	1.0	27
9	Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA. <i>Patient</i> , 2019, 12, 513-526.	1.1	24
10	Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives. <i>Patient</i> , 2021, 14, 119-128.	1.1	23
11	Risks in Antibiotic Substitution Following Medicine Shortage: A Health-Care Failure Mode and Effect Analysis of Six European Hospitals. <i>Frontiers in Medicine</i> , 2020, 7, 157.	1.2	20
12	Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. <i>Drug Discovery Today</i> , 2021, 26, 399-415.	3.2	20
13	Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US. <i>Frontiers in Pharmacology</i> , 2019, 10, 1009.	1.6	16
14	Patient Centricity in Patient Preference Studies: The Patient Perspective. <i>Frontiers in Medicine</i> , 2020, 7, 93.	1.2	14
15	Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey. <i>Haemophilia</i> , 2021, 27, 957-966.	1.0	14
16	Patient Involvement in the Lifecycle of Medicines According to Belgian Stakeholders: The Gap Between Theory and Practice. <i>Frontiers in Medicine</i> , 2018, 5, 285.	1.2	13
17	Patient Preferences in Rare Diseases: A Qualitative Study in Neuromuscular Disorders to Inform a Quantitative Preference Study. <i>Patient</i> , 2021, 14, 601-612.	1.1	8
18	Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia. <i>Frontiers in Medicine</i> , 2021, 8, 595797.	1.2	8

#	ARTICLE	IF	CITATIONS
19	Practical Implications From European Hospital Pharmacists on Prospective Risk Assessment for Medicine Shortages. <i>Frontiers in Medicine</i> , 2020, 7, 407.	1.2	6
20	Examining patient and professional perspectives in the UK for gene therapy in haemophilia. <i>Haemophilia</i> , 2022, 28, 588-609.	1.0	5
21	Improving Patient Involvement in the Lifecycle of Medicines: Insights From the EUPATI BE Survey. <i>Frontiers in Medicine</i> , 2020, 7, 36.	1.2	4
22	A study protocol for quantifying patient preferences in neuromuscular disorders: a case study of the IMI PREFER Project. <i>Wellcome Open Research</i> , 2020, 5, 253.	0.9	4